DLBCL is the most common type of adult Non-Hodgkin Lymphoma (NHL). Exact incidence of DLBCL in our county is not known but it comprises 30 40% of NHL in North America & Europe. Most recent WHO classification recognizes 13 subtypes … Continue reading →
Background: Diffuse large cell B-cell lymphoma (DLBCL) the single largest category of lymphoma, is a heterogenous group of malignant lymphomas with several morphologic features. Objective: To know the outcome and survival of subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) after … Continue reading →
Amir Ali Hamidieh, Maryam Behfar Thalassaemia major (TM) is one of the most common hereditary haematologic disorder with insufficient production of red blood cells. Although regular blood transfusion relieves the complication such as anaemia, bone marrow expansion, heart failure and … Continue reading →
M B Agarwal Acute myeloblastic leukaemia (AML) is a heterogeneous disease where patients can be cured while others can succumb within a few days of diagnosis and beginning treatment. The major reason for non-curability is resistance to present treatment. Treatment … Continue reading →
Selva Titus Chacko Although all hospitalized patients are at risk for acquiring health care-associated infections (HAIs), those with malignancy- specifically solid tumours, haematological malignancies and those treated with chemotherapy and Hematopoietic stem cell transplants are at increased risk. These patients … Continue reading →
M B Agarwal Myelodysplastic syndrome (MDS) is a disease of elderly, characterized by ineffective haematopoiesis leading to cytopenia and a high risk of progression to Acute Myeloid Leukaemia (AML). Diagnosis is based on morphological assessment of blood and marrow, karyotyping … Continue reading →
Amin Islam Backgrounds: Targeted and Immunotherapy have changed treatment practices for many haematological malignancies. Even in the current era of targeted, immunotherapies and check point inhibitors, chemotherapy remains the backbone of treatment for many haematological malignancies. Application of novel immunotherapies … Continue reading →
Anup J Devasia Multiple myeloma is a malignant neoplasm characterised by clonal disorder of terminally differentiated plasma cells. Dramatic advancements have happened in the treatment algorithm in the last 2 decades which has led to improvement in survival and overall … Continue reading →
Sachi Satapathy Till date, 1,748 Haemophilia patients have been identified in Bangladesh. However, to go by the prevalence rate, there could be 11,000 haemophilia patients and people with other inherited bleeding disorders in the country. At this moment, many families … Continue reading →
Daniel Hart Haemophilia care is evolving rapidly. Clotting factor concentrates (CFC) are increasingly available as either plasma derived or recombinant types. Recently, new recombinant CFC products have extended half-life technologies (e.g. Elocta, Alprolix). Examples of all these types of CFC … Continue reading →
